NovImmune SA Strengthens Board and Management Team

GENEVA--(BUSINESS WIRE)--NovImmune SA announced the addition of Michael Steinmetz, Ph.D. to its Board of Directors and David Slack as Head of Corporate & Business Development

Dr. Steinmetz brings over 25 years of industry and investment experience within the healthcare sector. Since its inception in 2005, he has served as Managing Director of Clarus Ventures, a US$1.2 billion biotechnology investment fund based in the Boston area.

Back to news